title: Cyclooxygenase inhibitor improved an exudative lesion of choroidal neovascularization in age-related macular degeneration.
abstract: OBJECTIVE
  To report a case in which a nonselective cyclooxygenase (COX) inhibitor improved an exudative lesion in age-related macular degeneration.
  
  
  RESULTS
  A 64-year-old man had a complaint of metamorphopsia in the left eye. Visual acuity was 0.5 in the left eye. Fluorescein angiography and indocyanine angiography showed juxtafoveal occult choroidal neovascularization (CNV) in the left eye, and pegaptanib sodium 0.3 mg was administered once every 6 weeks. After 4 months, visual acuity improved to 0.8. After 8 months follow-up, optical coherence tomography (OCT) showed subretinal fluid (SRF) and retinal pigment epithelium (RPE) irregularity. Visual acuity was 0.4. We recommended further pegaptanib sodium injections, but the patient did not consent to the treatment. Onset of cellulitis of the left toe occurred 1 week before the scheduled visit after 9 months. The patient was treated with loxoprofen sodium (nonselective COX inhibitor) and cefdinir for 7 days. At 2 weeks after onset of cellulitis, SRF had disappeared and OCT showed improvement of RPE irregularity.
  
  
  CONCLUSIONS
  A COX inhibitor had an effect on vascular permeability in CNV and may have improved exudative changes.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan.
authors.forename: Misa
authors.initials: M
authors.lastname: Suzuki
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Suzuki
authors.forename: Aoi
authors.initials: A
authors.lastname: Nagano
authors.forename: Manabu
authors.initials: M
authors.lastname: Hirasawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Sakuyama
authors.forename: Nobuhisa
authors.initials: N
authors.lastname: Mizuki
mesh_terms: D000284:Administration, Oral; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002199:Capillary Permeability; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004396:Coloring Agents; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D005122:Exudates and Transudates; D005451:Fluorescein Angiography; D006801:Humans; D007208:Indocyanine Green; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010666:Phenylpropionates / Q000627:therapeutic use*; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D004396:Coloring Agents; D016861:Cyclooxygenase Inhibitors; D010666:Phenylpropionates; C040656:loxoprofen; D007208:Indocyanine Green